BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

893 related articles for article (PubMed ID: 22232209)

  • 21. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis.
    Matsuura T; Maru Y; Izumiya M; Hoshi D; Kato S; Ochiai M; Hori M; Yamamoto S; Tatsuno K; Imai T; Aburatani H; Nakajima A; Hippo Y
    Carcinogenesis; 2020 Jun; 41(4):490-501. PubMed ID: 31233118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of Pancreatic Inflammation Accelerates Pancreatic Tumorigenesis in Mice.
    Zhuang L; Zhan X; Bi Y; Ji B
    Methods Mol Biol; 2019; 1882():287-297. PubMed ID: 30378063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.
    Morris JP; Cano DA; Sekine S; Wang SC; Hebrok M
    J Clin Invest; 2010 Feb; 120(2):508-20. PubMed ID: 20071774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.
    Ganaie AA; Siddique HR; Sheikh IA; Parray A; Wang L; Panyam J; Villalta PW; Deng Y; Konety BR; Saleem M
    Mol Carcinog; 2020 Aug; 59(8):886-896. PubMed ID: 32291806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice.
    Bai H; Li H; Zhang W; Matkowskyj KA; Liao J; Srivastava SK; Yang GY
    Carcinogenesis; 2011 Nov; 32(11):1689-96. PubMed ID: 21859833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.
    Song HY; Biancucci M; Kang HJ; O'Callaghan C; Park SH; Principe DR; Jiang H; Yan Y; Satchell KF; Raparia K; Gius D; Vassilopoulos A
    Oncotarget; 2016 Dec; 7(49):80336-80349. PubMed ID: 27637077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy.
    Kong B; Bruns P; Behler NA; Chang L; Schlitter AM; Cao J; Gewies A; Ruland J; Fritzsche S; Valkovskaya N; Jian Z; Regel I; Raulefs S; Irmler M; Beckers J; Friess H; Erkan M; Mueller NS; Roth S; Hackert T; Esposito I; Theis FJ; Kleeff J; Michalski CW
    Gut; 2018 Jan; 67(1):146-156. PubMed ID: 27646934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.
    Carrière C; Young AL; Gunn JR; Longnecker DS; Korc M
    Biochem Biophys Res Commun; 2009 May; 382(3):561-5. PubMed ID: 19292977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.
    Taparra K; Wang H; Malek R; Lafargue A; Barbhuiya MA; Wang X; Simons BW; Ballew M; Nugent K; Groves J; Williams RD; Shiraishi T; Verdone J; Yildirir G; Henry R; Zhang B; Wong J; Wang KK; Nelkin BD; Pienta KJ; Felsher D; Zachara NE; Tran PT
    J Clin Invest; 2018 Nov; 128(11):4924-4937. PubMed ID: 30130254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
    Ardito CM; Grüner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT
    Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation.
    von Figura G; Morris JP; Wright CV; Hebrok M
    Gut; 2014 Apr; 63(4):656-64. PubMed ID: 23645620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis.
    Wang L; Yang H; Abel EV; Ney GM; Palmbos PL; Bednar F; Zhang Y; Leflein J; Waghray M; Owens S; Wilkinson JE; Prasad J; Ljungman M; Rhim AD; Pasca di Magliano M; Simeone DM
    Genes Dev; 2015 Jan; 29(2):171-83. PubMed ID: 25593307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.
    Schofield HK; Zeller J; Espinoza C; Halbrook CJ; Del Vecchio A; Magnuson B; Fabo T; Cali Daylan AE; Kovalenko I; Lee HJ; Yan W; Feng Y; Karim SA; Kremer DM; Kumar-Sinha C; Lyssiotis CA; Ljungman M; Morton JP; Galbán S; Fearon ER; Pasca di Magliano M
    JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming.
    Velez-Delgado A; Donahue KL; Brown KL; Du W; Irizarry-Negron V; Menjivar RE; Lasse Opsahl EL; Steele NG; The S; Lazarus J; Sirihorachai VR; Yan W; Kemp SB; Kerk SA; Bollampally M; Yang S; Scales MK; Avritt FR; Lima F; Lyssiotis CA; Rao A; Crawford HC; Bednar F; Frankel TL; Allen BL; Zhang Y; Pasca di Magliano M
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1673-1699. PubMed ID: 35245687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and Reversion of Pancreatic Tumorigenesis through a Differentiation-Based Mechanism.
    Krah NM; Narayanan SM; Yugawa DE; Straley JA; Wright CVE; MacDonald RJ; Murtaugh LC
    Dev Cell; 2019 Sep; 50(6):744-754.e4. PubMed ID: 31422917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.